New semisynthetic teicoplanin derivatives have comparable in vitro activity to that of oritavancin against clinical isolates of VRE

Zsolt Szűcs, Eszter Ostorházi, Máté Kicsák, Lajos Nagy, A. Borbás, P. Herczegh

Research output: Contribution to journalArticle

Abstract

Ten analogues of a teicoplanin pseudoaglycon derivative have been synthesized with the aim of optimizing the in vitro activity of the compound against VanA type vancomycin resistant enterococci (VRE) isolated from hospitalized patients. Teicoplanin, vancomycin, and oritavancin were used as reference antibiotics for the antibacterial evaluations. One of the new derivatives exhibited far superior activity than the original compound. The in vitro MICs measured were comparable to that of oritavancin against the investigated VRE strains.

Original languageEnglish
JournalJournal of Antibiotics
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

oritavancin
Teicoplanin
Vancomycin
Anti-Bacterial Agents
Vancomycin-Resistant Enterococci
In Vitro Techniques

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

New semisynthetic teicoplanin derivatives have comparable in vitro activity to that of oritavancin against clinical isolates of VRE. / Szűcs, Zsolt; Ostorházi, Eszter; Kicsák, Máté; Nagy, Lajos; Borbás, A.; Herczegh, P.

In: Journal of Antibiotics, 01.01.2019.

Research output: Contribution to journalArticle

@article{fb1f8875cf7b4c3bad9f6a8663906e10,
title = "New semisynthetic teicoplanin derivatives have comparable in vitro activity to that of oritavancin against clinical isolates of VRE",
abstract = "Ten analogues of a teicoplanin pseudoaglycon derivative have been synthesized with the aim of optimizing the in vitro activity of the compound against VanA type vancomycin resistant enterococci (VRE) isolated from hospitalized patients. Teicoplanin, vancomycin, and oritavancin were used as reference antibiotics for the antibacterial evaluations. One of the new derivatives exhibited far superior activity than the original compound. The in vitro MICs measured were comparable to that of oritavancin against the investigated VRE strains.",
author = "Zsolt Szűcs and Eszter Ostorh{\'a}zi and M{\'a}t{\'e} Kics{\'a}k and Lajos Nagy and A. Borb{\'a}s and P. Herczegh",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41429-019-0164-1",
language = "English",
journal = "Journal of Antibiotics",
issn = "0021-8820",
publisher = "Japan Antibiotics Research Association",

}

TY - JOUR

T1 - New semisynthetic teicoplanin derivatives have comparable in vitro activity to that of oritavancin against clinical isolates of VRE

AU - Szűcs, Zsolt

AU - Ostorházi, Eszter

AU - Kicsák, Máté

AU - Nagy, Lajos

AU - Borbás, A.

AU - Herczegh, P.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Ten analogues of a teicoplanin pseudoaglycon derivative have been synthesized with the aim of optimizing the in vitro activity of the compound against VanA type vancomycin resistant enterococci (VRE) isolated from hospitalized patients. Teicoplanin, vancomycin, and oritavancin were used as reference antibiotics for the antibacterial evaluations. One of the new derivatives exhibited far superior activity than the original compound. The in vitro MICs measured were comparable to that of oritavancin against the investigated VRE strains.

AB - Ten analogues of a teicoplanin pseudoaglycon derivative have been synthesized with the aim of optimizing the in vitro activity of the compound against VanA type vancomycin resistant enterococci (VRE) isolated from hospitalized patients. Teicoplanin, vancomycin, and oritavancin were used as reference antibiotics for the antibacterial evaluations. One of the new derivatives exhibited far superior activity than the original compound. The in vitro MICs measured were comparable to that of oritavancin against the investigated VRE strains.

UR - http://www.scopus.com/inward/record.url?scp=85063048179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063048179&partnerID=8YFLogxK

U2 - 10.1038/s41429-019-0164-1

DO - 10.1038/s41429-019-0164-1

M3 - Article

JO - Journal of Antibiotics

JF - Journal of Antibiotics

SN - 0021-8820

ER -